During a mean follow-up of 9.6 months, adults receiving an SGLT2 inhibitor had a lower risk for a CV event than those receiving a GLP-1 receptor agonist (HR = 0.92
Clinical trials such as SURMOUNT-1 highlight significant weight loss benefits, positioning Zepbound as a fitting choice for achieving weight loss goals
Perfusion of glucose, sucrose, galactose, maltose, 3- O -methylglucose, and a - or B -methylglucoside significantly stimulate GIP secretion, while mannose, 6-deoxygalactose, 2-deoxyglucose, myoinositol, fructose or lactose do not (Sykes et al., 1980)
According to the MHRA's latest guidance, while occurrences are rare, there have been reports of severe, necrotizing, and even fatal pancreatitis associated with GLP-1 and GIP receptor agonists
Very interesting to see the evidence of the incredible ROI meeting with a Dietitian provides not only for the patient's health outcomes, but for Medicaid programs as well